AUGMENTIN 1gm In Skin And Soft Tissue Infection

An Open, Non-comparative Study to Evaluate the Efficacy and Safety of AUGMENTIN 1gm (875mg Amoxicillin/125mg Clavulanic Acid) po q 12 Hours in the Treatment of Uncomplicated Skin and Soft Tissue Infections in Pakistan

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00343135

Enrollment

195

Registered

2006-06-22

Start date

2004-12-31

Completion date

2005-03-31

Last updated

2012-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Soft Tissue, Skin Diseases, Infectious

Keywords

Skin, AUGMENTIN, 1gm, Soft, tissue, Infections

Brief summary

Study to evaluate the effects of AUGMENTIN 1gm in the treatment of Skin and Soft tissue infections

Interventions

DRUGamoxicillin/clavulanate potassium 1gm

amoxicillin/clavulanate potassium 1gm

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* having diagnosed uncomplicated soft tissue infection (e.g furuncle, cellulitis) * has given freely documented consent.

Exclusion criteria

* antibiotics * have renal or hepatic insufficiency * systemic toxicity * pregnancy * lactation * hypersensitivity to penicillin or Beta-lactam antibiotics

Design outcomes

Primary

Measure	Time frame
Clinical response at 10 - 14 days post therapy	10 - 14 days

Secondary

Measure	Time frame
Clinical response at on-therapy evaluation visit (2 - 4 days following initiation of therapy and 48 - 96 hours post therapy) Bacteriological response at (2 - 4 days following initiation of therapy, 48 - 96 hours post therapy, 10 - 14 days post therapy)	2 - 4 days

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026